Actavis wins FDA approval for ANDA of generic Opana ER
Specialty pharmaceutical company Actavis has won FDA approval for abbreviated new drug application (ANDA) of generic equivalent to Endo Health Solutions' Opana ER.
Oxymorphone Hydrochloride extended-release tablets, which is available in doses 5mg, 10mg, 20mg, 30mg and 40mg, is the ANDA product indicated for the relief of moderate to severe pain in patients who need continuous opioid treatment for an extended period of time.
Opana ER is an opioid agonist that was previously marketed and was voluntarily withdrawn from sale in 2012.
Total US sales of Opana ER tablets were approximately $461m for the 12 months ending on 31 May 2013, according to IMS Health data.
The company had earlier received approval and is currently marketing Oxymorphone Hydrochloride extended-release tablets 7.5mg and 15mg for which it is currently defending ongoing patent litigation that was initiated by Endo.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250